RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b

J Neuroimmunol. 2000 Jul 10;107(1):100-7. doi: 10.1016/s0165-5728(00)00261-7.

Abstract

RANTES (regulated upon activation, normal T-cell expressed and secreted), a CC chemokine, appears to play a role in the pathogenesis of relapsing-remitting multiple sclerosis (RR-MS), enhancing the inflammatory response within the nervous system. We have demonstrated that RANTES production is increased in RR-MS compared to controls. Interferon-beta-1b (IFN-beta-1b) treatment reduces RANTES production in sera and peripheral blood adherent mononuclear cell (PBAM) supernatants both in relapse and remission. IFN-beta-1b also reduces RANTES expression in PBAM. Our results suggest that RANTES modulation might represent one of the mechanisms of action of IFN-beta-1b in RR-MS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Adult
  • Chemokine CCL5 / biosynthesis
  • Chemokine CCL5 / blood
  • Chemokine CCL5 / genetics
  • Chemokine CCL5 / metabolism*
  • Female
  • Humans
  • Interferon beta-1a
  • Interferon beta-1b
  • Interferon-beta / therapeutic use*
  • Male
  • Middle Aged
  • Monocytes / drug effects
  • Monocytes / metabolism
  • Multiple Sclerosis, Relapsing-Remitting / blood
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / metabolism*
  • Phytohemagglutinins / pharmacology
  • RNA, Messenger / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Adjuvants, Immunologic
  • Chemokine CCL5
  • Phytohemagglutinins
  • RNA, Messenger
  • Interferon beta-1b
  • Interferon-beta
  • Interferon beta-1a